1. |
Chemotherapy of metastatic colorectal cancer[J].Prescrire Int,2010,19(109):219-224.
|
2. |
Cai X,Cao W,Ding H,et al.Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
|
3. |
杨学宁,吴一龙.实体瘤治疗疗效评价标准RECIST[J].循证医学,2004,4(2):85-111.
|
4. |
周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:606.
|
5. |
Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1993,56(11):2602-2606.
|
6. |
Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts[J].Jpn J Cancer Res,1987,78(8):748-755.
|
7. |
Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993,53(17):4004-4009.
|
8. |
Van den Brande J,Schöffski P,Schellens JH,et al.EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer[J].Br J Cancer,2003,88(5):648-653.
|
9. |
Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J].Ann Oncol,2009,20(5):892-896.
|
10. |
Hong YS,Park YS,Lim HY,et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer:a randomised,non-inferiority phase 3 trial[J].Lancet Oncol,2012,13(11):1125-1132.
|